Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Collection

Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis

Bone Marrow Transplantation volume 41, pages 239–244 (2008)Cite this article

Abstract

Some reports suggest that blood stem cell mobilization is difficult in a proportion of patients with CLL. We evaluated this issue in a large cohort of CLL patients. One hundred and twenty-eight patients with CLL underwent blood stem cell mobilization during 1995–2005 in Finland. Ninety-five percent of the patients had received fludarabine. The most common mobilization regimen was intermediate-dose CY plus G-CSF (90 patients, 70%). At least 2 × 106/kg CD34+ cells were collected after the first mobilization attempt in 83 patients (65%), whereas 45 patients (35%) failed to reach this collection target. No differences were observed between these patient groups with regard to age, time from the diagnosis to mobilization, number of previous treatment lines, number of fludarabine courses, time from the last fludarabine-containing chemotherapy to mobilization, disease status or degree of marrow infiltration. Patients who failed collection had platelets <100 × 109/l more commonly at the time of mobilization (30 vs 4%, P<0.001). A significant proportion of patients with CLL were difficult to mobilize. Adequate marrow function including platelet counts >100 × 109/l seem to be important factors in terms of successful blood stem cell collection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberration and survival in chronic lymphocytic leukaemia. N Engl J Med 2000; 343: 1910–1916.

    Article  PubMed  Google Scholar 

  2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V/(H) genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  3. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd KL et al. Fludarabine compared with chlorambucil as primary therapy in patients with chronic lymphocyte leukaemia. N Engl J Med 2000; 343: 1750–1757.

    Article  CAS  PubMed  Google Scholar 

  4. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy in younger patients with chronic lymphocytic leukaemia. Blood 2006; 107: 885–891.

    Article  CAS  PubMed  Google Scholar 

  5. Elter T, Borchmann P, Schul H, Reiser M, Trelle S, Schnell R et al. Fludabine combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia: results of a phase II trial. J Clin Oncol 2005; 23: 7024–7031.

    Article  CAS  PubMed  Google Scholar 

  6. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine; results of a large international study. Blood 2002; 99: 3554–3561.

    Article  CAS  PubMed  Google Scholar 

  7. Dreger P, Stilgenbauer S, Benner A, Ritgen M, Kröber A, Kneba M et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850–2858.

    Article  CAS  PubMed  Google Scholar 

  8. Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397–404.

    Article  CAS  PubMed  Google Scholar 

  9. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jantunen E, Itälä M, Siitonen T, Juvonen E, Koivunen E, Koistinen P et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplant 2006; 37: 1093–1098.

    Article  CAS  PubMed  Google Scholar 

  11. Itälä M, Pelliniemi T-T, Rajamäki A, Remes K . Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilisation predicts the stem cell yield. Bone Marrow Transplant 1997; 19: 647–651.

    Article  PubMed  Google Scholar 

  12. Tournilhac O, Cazin B, Leprerre S, Divine M, Maloum K, Delmer A et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363–365.

    Article  PubMed  Google Scholar 

  13. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  PubMed  Google Scholar 

  14. Scime R, Indovina A, Santoro A, Musso M, Olivieri A, Tringali S et al. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplant 1998; 22: 1159–1165.

    Article  CAS  PubMed  Google Scholar 

  15. Montillo M, Tedeschi A, Rossi V, Cairoli R, Pungoline E, Intropido L et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia 2004; 18: 57–62.

    Article  CAS  PubMed  Google Scholar 

  16. Sutton L, Genet P, Tournilhac O, Divine M, Leblond V, Martin C et al. PBSC mobilization in CLL patients: impact of previous treatment with fludarabine. Bone Marrow Transplant 2007; 39 (Suppl 1): S7; abstract.

    Google Scholar 

  17. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242.

    Article  CAS  PubMed  Google Scholar 

  18. Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade lymphoma patients. Leuk Lymphoma 2000; 37: 157–161.

    Article  CAS  PubMed  Google Scholar 

  19. Micallef I, Apostolidis J, Rohatiner A, Wiggins C, Crawley CR, Foran JM et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367–373.

    Article  CAS  PubMed  Google Scholar 

  20. Michallet M, Thiebaut A, Dreger P, Remes K, Milpied N, Santini G et al. Peripheral blood stem cell (PBSC) mobilisation and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: 595–601.

    Article  CAS  PubMed  Google Scholar 

  21. Lysak D, Koza V, Steinerova K, Jindra P, Vozobulova V, Schutzova M . Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005; 84: 456–461.

    Article  CAS  PubMed  Google Scholar 

  22. Sutton L, Maloum K, Gonzalez H, Zouabi H, Azar N, Boccacio C et al. Autologous hematopoietic stem cell transplantation for advanced B cell chronic lymphocytic leukaemia. Leukemia 1998; 12: 1699–1707.

    Article  CAS  PubMed  Google Scholar 

  23. de la Rubia J, Blade J, Lahuerta JJ, Ribera JM, Martinez R, Alegre A et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) study. Haematologica 2006; 91: 621–627.

    CAS  PubMed  Google Scholar 

  24. Jantunen E, Kuittinen T, Penttilä K, Lehtonen P, Mahlamäki E, Nousiainen T . High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917–922.

    Article  CAS  PubMed  Google Scholar 

  25. Lefrere F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant 2006; 37: 725–729.

    Article  CAS  PubMed  Google Scholar 

  26. Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S et al. Progenitor cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–546.

    Article  CAS  PubMed  Google Scholar 

  27. Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW et al. Favourable treatment outcome in non-Hodgkin's lymphoma patients with ‘poor’ mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506–512.

    Article  CAS  PubMed  Google Scholar 

  28. Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002; 30: 273–278.

    Article  CAS  PubMed  Google Scholar 

  29. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E . Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907–912.

    Article  CAS  PubMed  Google Scholar 

  30. Jantunen E, Leppä S, Kuittinen T, Keskinen L, Kuittinen O, Mokka M et al. (2007) Cyclophosphamide or disease-specific chemotherapy for progenitor cell mobilisation in patients with relapsed diffuse large B-cell lymphoma. Bone Marrow Transplant 2007; 39 (Suppl 1): S152; abstract.

    Google Scholar 

  31. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J et al. Indications for allogeneic stem cell transplantation in chronic lymphocyte leukaemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17.

    Article  CAS  PubMed  Google Scholar 

  32. Brugiatelli M, Banini G, Barosi G, Lauria F, Liso V, Marchetti M et al. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006; 91: 1662–1673.

    PubMed  Google Scholar 

  33. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF. Blood 2005; 106: 1867–1874.

    Article  CAS  PubMed  Google Scholar 

  34. Calandra G, McCarty J, McGuirk J, Barlogie B, Crocker S-A, Badel K . AMD3100 plus G-CSF mobilizes the majority of non-Hodgkin lymphoma, multiple myeloma and Hodgkin's disease patients who failed prior mobilization with other regimens. Bone Marrow Transplant 2007; 39 (Suppl 1): S41; abstract.

    Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Blood Disease Research Foundation and EVO funding by Kuopio University Hospital.

Author information

Authors and Affiliations

  1. Department of Medicine, Kuopio University Hospital, Kuopio, Finland

    E Jantunen, T Kuittinen & T Nousiainen

  2. Department of Medicine, Turku University Central Hospital, Turku, Finland

    M Itälä & K Remes

  3. Department of Medicine, Oulu University Hospital, Oulu, Finland

    T Siitonen & P Koistinen

  4. Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

    J Heiskanen, E Juvonen & L Volin

  5. Department of Medicine, Tampere University Hospital, Tampere, Finland

    E Koivunen & R Silvennoinen

Authors
  1. E Jantunen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Itälä
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Siitonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Kuittinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Heiskanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Koivunen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Juvonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Silvennoinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Nousiainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Koistinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L Volin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K Remes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Jantunen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jantunen, E., Itälä, M., Siitonen, T. et al. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplant 41, 239–244 (2008). https://doi.org/10.1038/sj.bmt.1705897

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705897

Keywords

This article is cited by

Search

Advanced search

Quick links